Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Drug-resistant TB news

Show

From To
Ukraine’s TB problem is ticking time bomb for Europe

Controlling the airborne disease takes on additional urgency this year as the country seeks to integrate into EU with a new visa-free regime.

Published
29 August 2017
From
Politico
X-DR TB emerged in 1990s in South Africa fueled by HIV

Extensively drug resistant tuberculosis emerged and was widely transmitted in South Africa long before it was spotted by public health surveillance efforts, and at least a decade earlier than the first reported outbreak in 2005, a  presentation Monday showed.

Published
26 July 2017
From
Science Speaks
We had to run our own trial for TB drugs – nobody else was doing it

Four years ago, Médecins Sans Frontières (MSF) made the decision to sponsor and run its own tuberculosis clinical trial. The aim was to find a new treatment regimen for drug-resistant tuberculosis (TB) that was radically better than what was currently available. As an organisation that specialises in delivering short-term emergency healthcare, this was a bold and new direction to take. But it was a decision that came from our frustration, anger and impatience on behalf of the more than 20,000 people with TB that we treat every year. We felt compelled to search for improved treatments ourselves because too few pharmaceutical companies, organisations or universities were doing enough about it.

Published
02 June 2017
From
The Guardian
MDR-TB numbers could keep growing despite improved treatment

Up to one-in-three tuberculosis cases in Russia could be multidrug resistant by 2040, and one-in-eight in India, unless more is done to stop the person-to-person

Published
11 May 2017
By
Keith Alcorn
Multidrug-resistant tuberculosis in migrants, multi-country cluster

A multi-country cluster of multidrug-resistant tuberculosis (MDR TB) involving 28 migrants has been delineated by whole genome sequencing (WGS) in migrants recently having arrived from countries in the Horn of Africa. Although the number of cases detected so far is small, there is a possibility that more cases associated with this cluster may still be identified.

Published
14 April 2017
From
ECDC
Tuberculosis: Fewer than five per cent of people in need are treated with new drugs

Outside of a small number of clinical trials and compassionate use programmes, only 469 people received delamanid in 2016, while just over 4,300 received bedaquiline. All other people receiving DR-TB treatment continue instead to be treated with older, more toxic regimens that cure only 50 per cent of people treated, and cause severe side-effects, ranging from deafness to psychosis.

Published
27 March 2017
From
Médecins Sans Frontières (MSF) International
TB Alliance Sublicenses Promising Anti-tuberculosis Drug from the Medicines Patent Pool

On World Tuberculosis Day, TB Alliance and the Medicines Patent Pool (MPP) announced a licensing agreement for the clinical development of sutezolid, an antibiotic drug candidate which demonstrated encouraging results in early studies. The sublicense pertains to the development of sutezolid in combination with other TB drugs and follows the MPP's license for the treatment signed with patent holder The Johns Hopkins University in January.

Published
24 March 2017
From
Yahoo Finance
New Tuberculosis Drugs May Become Ineffective: Study

New antibiotics that could treat tuberculosis may rapidly become ineffective, according to new research published by the Lancet ahead of World Tuberculosis Day. The rise in multi-drug resistant tuberculosis, which affected 480,000 people in 2015, could mean that even newly discovered drugs will soon be useless, the study found.

Published
24 March 2017
From
Inter Press Service
Rise of superbug tuberculosis hampers global control efforts

Rising rates of superbug tuberculosis (TB) are threatening to derail decades of progress against the contagious disease, experts said on Thursday, and new drugs powerful enough to treat them are few and far between.

Published
23 March 2017
From
Reuters
TB partners, patients ask: How does a bacterium responsible for nearly a third of drug-resistance deaths not make list of R&D priority pathogens?

While the unveiling of a list highlighting the need to fund drug development against specific pathogens represented just a beginning for some antimicrobial resistance fighting efforts, the list represented a setback for TB drug development, advocates say.

Published
02 March 2017
From
Science Speaks
← First12345...24Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.